← Eichor
Study identifier: NCT05949931 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma

Condition: Classic Hodgkin Lymphoma  ·  Sponsor: Sun Yat-sen University

PhasePhase 2
Planned participants108
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is conducted to evaluate the safety and efficiency of Penpulimab combined with AVD in patients with newly- diagnosed advanced classic Hodgkin lymphoma.

This description comes directly from the study's public registry record.

Talk to the study team

Qingqing Cai, MD. PhD.  ·  0086-20-87342823  ·  caiqq@sysucc.org.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen UniversityGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05949931